Submission Details
| 510(k) Number | K243274 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 16, 2024 |
| Decision Date | July 11, 2025 |
| Days to Decision | 268 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K243274 is an FDA 510(k) clearance for the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A SubTyping Kit (VER 4); Influenza B Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4), a Influenza A And Influenza B Multiplex Nucleic Acid Assay (Class II — Special Controls, product code OZE), submitted by Centers For Disease Control and Prevention (Atlanta, US). The FDA issued a Cleared decision on July 11, 2025, 268 days after receiving the submission on October 16, 2024. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3980.
| 510(k) Number | K243274 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 16, 2024 |
| Decision Date | July 11, 2025 |
| Days to Decision | 268 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | OZE — Influenza A And Influenza B Multiplex Nucleic Acid Assay |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.3980 |
| Definition | An Influenza A And Influenza B Multiplex Nucleic Acid Assay Is A Multiplex In Vitro Diagnostic Test For The Simultaneous Qualitative Detection And Discrimination Of Influenza A And Influenza B Nucleic Acids Isolated And Purified From Human Respiratory Specimens Obtained From Individuals Exhibiting Signs And Symptoms Of Respiratory Tract Infections Or Viral Culture. The Detection And Discrimination Of Influenza A And B Nucleic Acids From Symptomatic Patients Aid In The Diagnosis Of Human Respiratory Tract Influenza Viral Infections If Used In Conjunction With Other Clinical And Laboratory Findings. |